Quantitative systems pharmacology analysis of drug combination and scaling to humans : the interaction between noradrenaline and vasopressin in vasoconstriction
© 2018 The British Pharmacological Society..
BACKGROUND AND PURPOSE: Development of combination therapies has received significant interest in recent years. Previously, a two-receptor one-transducer (2R-1T) model was proposed to characterize drug interactions with two receptors that lead to the same phenotypic response through a common transducer pathway. We applied, for the first time, the 2R-1T model to characterize the interaction of noradrenaline and arginine-vasopressin on vasoconstriction and performed inter-species scaling to humans using this mechanism-based model.
EXPERIMENTAL APPROACH: Contractile data were obtained from in vitro rat small mesenteric arteries after exposure to single or combined challenges of noradrenaline and arginine-vasopressin with or without pretreatment with the irreversible α-adrenoceptor antagonist, phenoxybenzamine. Data were analysed using the 2R-1T model to characterize the observed exposure-response relationships and drug-drug interaction. The model was then scaled to humans by accounting for differences in receptor density.
KEY RESULTS: With receptor affinities set to published values, the 2R-1T model satisfactorily characterized the interaction between noradrenaline and arginine-vasopressin in rat small mesenteric arteries (relative standard error ≤20%), as well as the effect of phenoxybenzamine. Furthermore, after scaling the model to human vascular tissue, the model also adequately predicted the interaction between both agents on human renal arteries.
CONCLUSIONS AND IMPLICATIONS: The 2R-1T model can be of relevance to quantitatively characterize the interaction between two drugs that interact via different receptors and a common transducer pathway. Its mechanistic properties are valuable for scaling the model across species. This approach is therefore of significant value to rationally optimize novel combination treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:175 |
|---|---|
| Enthalten in: |
British journal of pharmacology - 175(2018), 16 vom: 02. Aug., Seite 3394-3406 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yin, Anyue [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0TTZ664R7Z |
|---|
| Anmerkungen: |
Date Completed 02.10.2019 Date Revised 09.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bph.14385 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM285041525 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM285041525 | ||
| 003 | DE-627 | ||
| 005 | 20231225044525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bph.14385 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0950.xml |
| 035 | |a (DE-627)NLM285041525 | ||
| 035 | |a (NLM)29859008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yin, Anyue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quantitative systems pharmacology analysis of drug combination and scaling to humans |b the interaction between noradrenaline and vasopressin in vasoconstriction |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2019 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 The British Pharmacological Society. | ||
| 520 | |a BACKGROUND AND PURPOSE: Development of combination therapies has received significant interest in recent years. Previously, a two-receptor one-transducer (2R-1T) model was proposed to characterize drug interactions with two receptors that lead to the same phenotypic response through a common transducer pathway. We applied, for the first time, the 2R-1T model to characterize the interaction of noradrenaline and arginine-vasopressin on vasoconstriction and performed inter-species scaling to humans using this mechanism-based model | ||
| 520 | |a EXPERIMENTAL APPROACH: Contractile data were obtained from in vitro rat small mesenteric arteries after exposure to single or combined challenges of noradrenaline and arginine-vasopressin with or without pretreatment with the irreversible α-adrenoceptor antagonist, phenoxybenzamine. Data were analysed using the 2R-1T model to characterize the observed exposure-response relationships and drug-drug interaction. The model was then scaled to humans by accounting for differences in receptor density | ||
| 520 | |a KEY RESULTS: With receptor affinities set to published values, the 2R-1T model satisfactorily characterized the interaction between noradrenaline and arginine-vasopressin in rat small mesenteric arteries (relative standard error ≤20%), as well as the effect of phenoxybenzamine. Furthermore, after scaling the model to human vascular tissue, the model also adequately predicted the interaction between both agents on human renal arteries | ||
| 520 | |a CONCLUSIONS AND IMPLICATIONS: The 2R-1T model can be of relevance to quantitatively characterize the interaction between two drugs that interact via different receptors and a common transducer pathway. Its mechanistic properties are valuable for scaling the model across species. This approach is therefore of significant value to rationally optimize novel combination treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Adrenergic alpha-Antagonists |2 NLM | |
| 650 | 7 | |a Phenoxybenzamine |2 NLM | |
| 650 | 7 | |a 0TTZ664R7Z |2 NLM | |
| 650 | 7 | |a Arginine Vasopressin |2 NLM | |
| 650 | 7 | |a 113-79-1 |2 NLM | |
| 650 | 7 | |a Norepinephrine |2 NLM | |
| 650 | 7 | |a X4W3ENH1CV |2 NLM | |
| 700 | 1 | |a Yamada, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Stam, Wiro B |e verfasserin |4 aut | |
| 700 | 1 | |a van Hasselt, Johan G C |e verfasserin |4 aut | |
| 700 | 1 | |a van der Graaf, Piet H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d 1968 |g 175(2018), 16 vom: 02. Aug., Seite 3394-3406 |w (DE-627)NLM000001325 |x 1476-5381 |7 nnns |
| 773 | 1 | 8 | |g volume:175 |g year:2018 |g number:16 |g day:02 |g month:08 |g pages:3394-3406 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bph.14385 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 175 |j 2018 |e 16 |b 02 |c 08 |h 3394-3406 | ||